Ablynx, Eddingpharm Sign Exclusive License Agreement
News Sep 02, 2014
Ablynx announced that it has expanded its relationship with Eddingpharm royalty-bearing license to develop and commercialise Ablynx’s anti-TNFα Nanobody®, ozoralizumab (ATN-103), in the mainland of the People’s Republic of China, the Hong Kong and Macao Special Administrative Regions, and Taiwan, for all indications, including rheumatoid arthritis (RA).
Ablynx will have access to the clinical data generated by Eddingpharm to support potential licensing discussions in other geographic regions.
Ablynx will receive an upfront payment of €2 million, payable in two tranches, and is entitled to receive development and commercial milestone payments plus tiered, double-digit royalties of up to 20%, based on annual net sales of ozoralizumab generated by Eddingpharm in Greater China.
Ozoralizumab is a next-generation TNFα blocker with clinical proof-of-concept in RA. The molecule consists of two Nanobodies targeting TNFα, which are linked to a Nanobody that binds to human serum albumin, extending the drug’s half-life in vivo and improving its distribution to inflamed joints. Clinical Phase IIa proof-of-concept was achieved in May 2011 in patients with active rheumatoid arthritis (RA), indicating that the highest dose of ozoralizumab (80 mg every 4 weeks) resulted in a statistically significant improvement of ACR20 responses compared with placebo at week 16. An open-label extension study over 48 weeks was well tolerated, adverse event rates were within expectations, serious infections remained rare, and no clinically meaningful immunogenicity could be observed. Clinical development of ozoralizumab was funded by Pfizer prior to Ablynx regaining the worldwide rights to develop and commercialise anti-TNFα Nanobodies in November 2011.
PhoreMost and o2h Discovery Collaborate to Progress First-in-Class Drug Discovery ProgramsNews
PhoreMost, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, announced it has entered into a collaboration with o2h discovery (o2h), an Anglo-Indian medicinal chemistry company that has in-house capability to take drug discovery programmes to the IND filing stage.READ MORE
Compound as Effective as FDA-Approved Drugs Against Life-Threatening InfectionsNews
Purdue University researchers have identified a new compound that in preliminary testing has shown itself to be as effective as antibiotics approved by the Food and Drug Administration to treat life-threatening infections while also appearing to be less susceptible to bacterial resistance.READ MORE
Chemists Design 'Mini-ecosystems' to Test Drug FunctionNews
Scripps Research scientists have solved a major problem in chemistry and drug development by using droplet-sized 'miniecosystems' to quickly see if a molecule can function as a potential therapeutic.READ MORE